DC-SCRIPT: AR and VDR regulator lost upon transformation of prostate epithelial cells

Prostate

Volumn 72, Issue 16, 2012, Pages 1708-1717

  Ansems, Marleen ^a   Karthaus, Nina ^a   Hontelez, Saartje ^a   Aalders, Tilly ^a   Looman, Maaike W ^a   Verhaegh, Gerald W ^a   Schalken, Jack A ^a   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgen Receptor; DC SCRIPT ZNF366; prostate carcinoma; Vitamin D3 Receptor

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; CYTOKERATIN; DC SCRIPT PROTEIN; MESSENGER RNA; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; BREAST EPITHELIUM; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DENDRITIC CELL; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

CARRIER PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CALCITRIOL;

EID: 84867890833     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22522     Document Type: Article

References (45)

1. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
2. Schalken JA,. Molecular aspects of hormone-independent prostate cancer. BJU Int 2007; 100 (Suppl 2): 52-55.
3. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA,. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995; 1 (9): 997-1003.
4. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L,. Inhibition of prostate cancer metastasis in vivo: A comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999; 8 (3): 241-248.
5. Krishnan AV, Peehl DM, Feldman D,. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 2003; 88 (2): 363-371.
6. Yang ES, Burnstein KL,. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003; 278 (47): 46862-46868.
7. Li X, Martinez-Ferrer M, Botta V, Uwamariya C, Banerjee J, Bhowmick NA,. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. Oncogene 2010.
8. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TL, Vessella RL, Palvimo JJ, Visakorpi T,. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004; 10 (3): 1032-1040.
9. Triantis V, Trancikova DE, Looman MW, Hartgers FC, Janssen RA, Adema GJ,. Identification and characterization of DC-SCRIPT, a novel dendritic cell-expressed member of the zinc finger family of transcriptional regulators. J Immunol 2006; 176 (2): 1081-1089.
10. Triantis V, Moulin V, Looman MW, Hartgers FC, Janssen RA, Adema GJ,. Molecular characterization of the murine homologue of the DC-derived protein DC-SCRIPT. J Leukoc Biol 2006; 79 (5): 1083-1091.
11. Ansems M, Hontelez S, Looman MW, Karthaus N, Bult P, Bonenkamp JJ, Jansen JH, Sweep FC, Span PN, Adema GJ,. DC-SCRIPT: Nuclear receptor modulation and prognostic significance in primary breast cancer. J Natl Cancer Inst 2010; 102 (1): 54-68.
12. Sieuwerts AM, Ansems M, Look MP, Span PN, de Weerd V, van Galen A, Foekens JA, Adema GJ, Martens JW,. Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: An independent retrospective validation study. Breast Cancer Res 2010; 12 (6): R103.
13. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN,. Normalization of gene expression measurements in tumor tissues: Comparison of 13 endogenous control genes. Lab Invest 2005; 85 (1): 154-159.
14. Liu A, Wei L, Gardner WA, Deng CX, Man YG,. Correlated alterations in prostate basal cell layer and basement membrane. Int J Biol Sci 2009; 5 (3): 276-285.
15. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, Klocker H, Wasylyk B, Voller M, Aalders T, Schalken JA, Oren M, Rotter V,. hTERT-immortalized prostate epithelial and stromal-derived cells: An authentic in vitro model for differentiation and carcinogenesis. Cancer Res 2006; 66 (7): 3531-3540.
16. Steketee K, Timmerman L, Ziel-van der Made AC, Doesburg P, Brinkmann AO, Trapman J,. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 2002; 100 (3): 309-317.
17. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J,. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997; 11 (2): 148-161.
18. Hayward SW, Rosen MA, Cunha GR,. Stromal-epithelial interactions in the normal and neoplastic prostate. Br J Urol 1997; 79 (Suppl 2): 18-26.
19. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T,. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 2004; 92 (4): 221-236.
20. Cunha GR, Hayward SW, Wang YZ,. Role of stroma in carcinogenesis of the prostate. Differentiation 2002; 70 (9-10): 473-485.
21. Balk SP, Knudsen KE,. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008; 6: e001.
22. Klotz L,. Hormone therapy for patients with prostate carcinoma. Cancer 2000; 88 (12 Suppl): 3009-3014.
23. Balk SP,. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002; 60 (3 Suppl 1): 132-138; discussion 138-139.
24. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C,. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999; 274 (12): 8316-8321.
25. Agoulnik IU, Vaid A, Bingman WE, 3rd, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL,. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005; 65 (17): 7959-7967.
26. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P, Kindle KB, Heery DM, Parker MG, Buluwela L, Kamalati T, Ali S,. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res 2006; 34 (21): 6126-6136.
27. Lonard DM,. O'Malley B W. Nuclear receptor coregulators: Judges, juries, and executioners of cellular regulation. Mol Cell 2007; 27 (5): 691-700.
28. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON,. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA 2010; 107 (6): 2610-2615.
29. Bonkhoff H, Remberger K,. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat Histopathol 1993; 422 (1): 35-38.
30. Wojno KJ, Epstein JI,. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol 1995; 19 (3): 251-260.
31. O'Malley FP, Grignon DJ, Shum DT,. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 1990; 417 (3): 191-196.
32. Man YG, Gardner WA,. Focal degeneration of basal cells and the resultant auto-immunoreactions: A novel mechanism for prostate tumor progression and invasion. Med Hypotheses 2008; 70 (2): 387-408.
33. Man YG, Gardner WA,. Bad seeds produce bad crops: A single stage-process of prostate tumor invasion. Int J Biol Sci 2008; 4 (4): 246-258.
34. Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, Massie CE, Vowler SL, Eldridge M, Carroll JS,. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev 2010; 24 (2): 171-182.
35. Hua S, Kittler R, White KP,. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 2009; 137 (7): 1259-1271.
36. Ansems M, Hontelez S, Karthaus N, Span PN, Adema GJ,. Crosstalk and DC-SCRIPT: Expanding Nuclear Receptor Modulation. Biochim Biophys Acta 2010.
37. Conzen SD,. Minireview: Nuclear receptors and breast cancer. Mol Endocrinol 2008; 22 (10): 2215-2228.
38. Bourdeau V, Deschenes J, Laperriere D, Aid M, White JH, Mader S,. Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells. Nucleic Acids Res 2008; 36 (1): 76-93.
39. Turner NC, Jones AL,. Management of breast cancer-part I. BMJ 2008; 337: a421.
40. Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N,. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci USA 2008; 105 (21): 7546-7551.
41. Rohan JN, Weigel NL,. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 2009; 150 (5): 2046-2054.
42. Zhao XY, Ly LH, Peehl DM, Feldman D,. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997; 138 (8): 3290-3298.
43. Zhao XY, Ly LH, Peehl DM, Feldman D,. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999; 140 (3): 1205-1212.
44. Bao BY, Hu YC, Ting HJ, Lee YF,. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 2004; 23 (19): 3350-3360.
45. Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO,. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Prostate 2008; 68 (7): 773-783.